BofA raised the firm’s price target on McKesson (MCK) to $755 from $665 and keeps a Buy rating on the shares. The recent introduction of tariffs on China and India, combined with the current administration’s changes to the FDA, could “create a perfect storm leading to generic inflation,” says the analyst, who highlights upside in the case of generic inflation for Cardinal Health (CAH), McKesson and Cencora (COR).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCK:
- McKesson downgraded to Hold from Buy at CFRA
- McKesson price target raised to $690 from $630 at Mizuho
- McKesson price target lowered to $692 from $700 at Deutsche Bank
- McKesson price target raised to $745 from $642 at Morgan Stanley
- McKesson: Strong Performance and Strategic Positioning Drive Buy Rating